The onset of motor neurone disease (MND) left Sarah without a voice and the use of her hands at the age of 34. It was within ...

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are among the most ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

Amyotrophic Lateral Sclerosis or ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS typically causes muscle atrophy, difficulty in breathing ...

Home NICE Guidance Conditions and diseases Neurological conditions Motor neurone disease Amyotrophic lateral sclerosis - SAR443820 [ID6386] In development [GID-TA11476] Expected publication date: TBC ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.